Alector Inc.
ALECDrugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How ALEC's past catalysts played out
AL001
Frontotemporal Dementia
AL002
Alzheimer Disease
GSK4527226
Alzheimer's Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
AL001 | Phase 3 | Frontotemporal Dementia | - | - |
AL002 | Phase 2 | Alzheimer Disease | - | - |
GSK4527226 | Phase 2 | Alzheimer's Disease | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Alector Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Alector Inc.'s (ALEC) pipeline across Phase 3, Phase 2. Its lead program is AL001 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Alector Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Alector Inc. (ALEC) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ALEC biotech catalysts?→
Add ALEC to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Alector Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.